Summary
Dr. Reddy's will delay supplies of semaglutide, the active ingredient in popular diabetes and weight loss drugs, due to a quality issue, causing its shares to be affected.
Dr. Reddy's to delay semaglutide supplies due to quality issue, shares decline
HyperFast News
Related news
Dr. Reddy's Enters India's Biosimilar Immuno-Oncology Market with Nivorz Launch
19 Sept 2026, 3:41 pm · News
Dr. Reddy's Aurigene Signs Long-Term Manufacturing Pact with Global Pharma Major
19 Sept 2026, 3:41 pm · News
Dr. Reddy's, Novartis India Terminate Agreement; Novartis Reacquires Product Rights
19 Sept 2026, 3:41 pm · News
